Odyssey Therapeutics: $213 Million Series D Closed For Advancing Autoimmune Disease Pipeline
By Amit Chowdhry ● Sep 14, 2025
Odyssey Therapeutics, a clinical-stage biopharmaceutical company, has closed an oversubscribed $213 million Series D financing to accelerate the development of its portfolio of medicines targeting autoimmune and inflammatory diseases. The round included participation from all existing investors and welcomed new backers, including Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Ventures, TPG Life Sciences Innovations, and Wedbush Healthcare Partners.